FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Hydroxyzine Pamoate Oral Capsules
Status: Resolved
»Duration of Shortage: 03/12/2019 - 02/17/2021
»Therapeutic Categories: Psychiatry

Expand all

Heritage Pharma (Revised 02/17/2021)

Company Contact Information:
855-228-9470

Presentation
  • Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01)
  • Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05)
  • Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01)
  • Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05)
Note:
  • N/A

Impax Laboratories (Revised 02/17/2021)

Company Contact Information:
877-835-5472

Presentation
  • Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01)
  • Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02)
  • Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01)
  • Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02)
Note:
  • N/A

Pfizer Pharmaceuticals (Revised 02/17/2021)

Company Contact Information:
800-533-4535

Presentation
  • Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66)
  • Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66)
Note:
  • N/A

Sandoz (Revised 02/17/2021)

Company Contact Information:
800-525-8747

Presentation
  • 25 mg 100 count (NDC 0185-0674-01)
  • 25 mg 500 count (NDC 0185-0674-05)
Note:
  • N/A

Teva Pharmaceuticals (Revised 02/17/2021)

Company Contact Information:
800-545-8800

Presentation
  • 100 mg 100 count (NDC 0555-0324-02)
  • 25 mg 100 count (NDC 0555-0323-02)
  • 25 mg 500 count (NDC 0555-0323-04)
  • 50 mg 100 count (NDC 0555-0302-02)
  • 50 mg 500 count (NDC 0555-0302-04)
Note:
  • N/A

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English